최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기대한 두경부 종양 학회지 = Korean journal of head & neck oncology, v.38 no.2, 2022년, pp.7 - 13
김진호 (서울대학교병원 방사선종양학과)
Human papillomavirus (HPV) is a causative agent for a subset of oropharyngeal cancer (OPC). The current standard of care (SOC) for locally advanced OPC is 70 Gy definitive radiotherapy (RT) concurrent with cisplatin, which entails significant proportions of acute and late grade 3 or higher toxicitie...
Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et?al. An Intergroup Phase III Comparison of Standard Radiation?Therapy and Two Schedules of Concurrent Chemoradiotherapy?in Patients With Unresectable Squamous Cell Head and Neck?Cancer. J Clin Oncol. 2003;21:92-98.
Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al.?Final Results of the 94-01 French Head and Neck Oncology and?Radiotherapy Group Randomized Trial Comparing Radiotherapy?Alone With Concomitant Radiochemotherapy in Advanced-Stage?Oropharynx Carcinoma. J Clin Oncol. 2004;22:69-76.
Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, et al.?Locoregionally advanced carcinoma of the oropharynx: Conventional?radiotherapy vs. accelerated hyperfractionated radiotherapy vs.?concomitant radiotherapy and chemotherapy-a multicenter?randomized trial. Int J Radiat Oncol Biol Phys. 2003;55: 78-92.
Jin IG, Kim JH, Wu HG, Hwang SJ. Effect of mesenchymal stem?cells and platelet-derived growth factor on the healing of radiation induced ulcer in rats. Tissue Eng Regen Med. 2016;13:78-90.
Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI,?Soulieres D, et al. Randomized Phase III Trial to Test?Accelerated Versus Standard Fractionation in Combination With?Concurrent Cisplatin for Head and Neck Carcinomas in the?Radiation Therapy Oncology Group 0129 Trial: Long-Term?Report of Efficacy and Toxicity. J Clin Oncol. 2014;32:3858-3867.
Zandberg DP, Cullen K, Bentzen SM, Goloubeva OG. Definitive?radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with?squamous cell carcinoma of the head and neck: Analysis of the?SEER-medicare linked database. Oral Oncol. 2018;86:132-140.
Parsons JT, Mendenhall WM, Stringer SP, Amdur RJ, Hinerman?RW, Villaret DB, et al. Squamous cell carcinoma of the oropharynx.?Cancer. 2002;94:2967-2980.
Bernier J, Cooper JS. Chemoradiation after surgery for high-risk?head and neck cancer patients: How strong is the evidence??Oncologist. 2005;10:215-224.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human Papillomavirus and Survival of Patients?with Oropharyngeal Cancer. N Engl J Med. 2010;363:24-35.
Petrelli F, Luciani A, Ghidini A, Cherri S, Gamba P, Maddalo M,?et al. Treatment de-escalation for HPV+ oropharyngeal cancer:?A systematic review and meta-analysis. Head Neck. 2022;44:1255-1266.
Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell?L, et al. Role of Treatment Deintensification in the Management?of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical?Opinion. J Clin Oncol. 2019;37:1578-1589.
National Comprehensive Cancer Network. NCCN Clinical Practice?Guidelines in Oncology, Head and Neck Cancers, Version 2.2022.
Cramer JD, Ferris RL, Kim S, Duvvuri U. Primary surgery for?human papillomavirus-associated oropharyngeal cancer: Survival?outcomes with or without adjuvant treatment. Oral Oncol. 2018;87:170-176.
Kang JJ, Yu Y, Chen L, Zakeri K, Gelblum DY, McBride SM, et?al. Consensuses, controversies, and future directions in treatment?deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin [Preprint]. 2022 [cited 2022?Oct 28];1-34. Available from: 10.3322/caac.21758
Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C,?Bourhis J, et al. Meta-analysis of chemotherapy in head and neck?cancer (MACH-NC): A comprehensive analysis by tumour site.?Radiother Oncol. 2011;100:33-40.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB,?et al. Radiotherapy plus cetuximab for squamous-cell carcinoma?of the head and neck. N Engl J Med. 2006;354:567-578.
Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM,?Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in?human papillomavirus-positive oropharyngeal cancer (NRG?Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40-50.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B,?Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab?in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled?phase 3 trial. Lancet. 2019;393:51-60.
Gebre-Medhin M, Brun E, Engstrom P, Haugen Cange H,?Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: A?Randomized Phase III Study Comparing Chemoradiotherapy?With Cisplatin Versus Cetuximab in Patients With Locoregionally?Advanced Head and Neck Squamous Cell Cancer. J Clin Oncol.?2021;39:38-47.
Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A,?et al. Randomized Trial of Radiation Therapy With Weekly?Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal?Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology?Group Study. Int J Radiat Oncol Biol Phys. 2021;111:876-886.
Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison?ML, Xia P, et al. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002).?J Clin Oncol. 2021;39:956-965.
Wang MB, Liu IY, Gornbein JA, Nguyen CT. HPV-Positive?Oropharyngeal Carcinoma: A Systematic Review of Treatment?and Prognosis. Otolaryngol Head Neck Surg. 2015;153:758-769.
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E,?et al. Radiotherapy versus transoral robotic surgery and neck?dissection for oropharyngeal squamous cell carcinoma (ORATOR):?An open-label, phase 2, randomised trial. The Lancet Oncology.?2019;20:1349-1359.
Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E,?et al. Randomized Trial of Radiotherapy Versus Transoral?Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma:?Long-Term Results of the ORATOR Trial. J Clin Oncol. 2022;40:866-875.
Nichols AC, Lang P, Prisman E, Berthelet E, Tran E, Hamilton S, et al. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral?surgery (ORATOR2): Study protocol for a randomized phase II?trial. BMC Cancer. 2020;20:125.
Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, et?al. Assessment of Toxic Effects and Survival in Treatment?Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The?ORATOR2 Phase 2 Randomized Clinical Trial. JAMA Oncol.?2022;8:845-851.
Quan DL, Sukari A, Nagasaka M, Kim H, Cramer JD. Gastrostomy?tube dependence and patient-reported quality of life outcomes?based on type of treatment for human papillomavirus-associated?oropharyngeal cancer: Systematic review and meta-analysis.?Head Neck. 2021;43:3681-3696.
Chera BS, Amdur RJ, Tepper JE, Tan X, Weiss J, Grilley-Olson?JE, et al. Mature results of a prospective study of deintensified?chemoradiotherapy for low-risk human papillomavirus-associated?oropharyngeal squamous cell carcinoma. Cancer. 2018;124:2347-2354.
Chera BS, Amdur RJ, Green R, Shen C, Gupta G, Tan X, et al.?Phase II Trial of De-Intensified Chemoradiotherapy for Human?Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.?J Clin Oncol. 2019;37:2661-2669.
Dagan R, Holtzman AL, Bryant CM, Mendenhall WM, Hitchcock?KE, Park J, et al. De-Intensified (DI) IMPT vs. IMRT(Chemo) for?HPV-Associated Oropharynx Cancer (HPV-OPC): Initial Quality?of Life (QOL) Results From a Prospective, Multi-Institutional?Trial. Int J Radiat Oncol Biol Phys. 2021;111 Suppl 3: e406-407.
Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al.?Reduced-dose radiotherapy for human papillomavirus-associated?squamous-cell carcinoma of the oropharynx: A single-arm,?phase 2 study. Lancet Oncol. 2017;18:803-811.
Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et?al. E1308: Phase II trial of induction chemotherapy followed by?reduced-dose radiation and weekly cetuximab in patients with?HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group. J Clin Oncol.?2017;35:490-497.
Misiukiewicz K, Gupta V, Miles BA, Bakst R, Genden E,?Selkridge I, et al. Standard of care vs reduced-dose chemo-radiation after induction chemotherapy in HPV+ oropharyngeal?carcinoma patients: The Quarterback trial. Oral Oncol. 2019;95:170-177.
Posner MR, Misiukiewicz K, Miles BA, Sharma S, Gupta V,?Genden EM, et al. Survival (OS) and progression-free survival?(PFS) results after induction chemotherapy (IC) followed by?de-escalated chemoradiotherapy (RDCRT) for locally advanced?(LA) HPV positive oropharynx cancer (HPVOPC). J Clin Oncol.?2021;39 Suppl 15:6058.
Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J,?et al. Risk and response adapted de-intensified treatment for?HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021;122:105566.
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N,?Melotek JM, et al. OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal?cancer. Ann Oncol. 2019;30:297-302.
Kim R, Hahn S, Shin J, Ock CY, Kim M, Keam B, et al. The?Effect of Induction Chemotherapy Using Docetaxel, Cisplatin,?and Fluorouracil on Survival in Locally Advanced Head and?Neck Squamous Cell Carcinoma: A Meta-Analysis. Cancer Res?Treat. 2016;48:907-916.
Lee NY, Sherman EJ, Schoder H, McBride SM, Yu Y, Kang J, et?al. The 30 ROC trial: Precision intra-treatment imaging guiding?major radiation reduction in human papillomavirus related oropharyngeal cancer. J Clin Oncol. 2021;39 Suppl 15:6019.
Riaz N, Sherman E, Pei X, Schoder H, Grkovski M, Paudyal R, et?al. Precision Radiotherapy: Reduction in Radiation for Oropharyngeal?Cancer in the 30 ROC Trial. J Natl Cancer Inst. 2021;113:742-751.
Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J,?Forastiere A, et al. Defining risk levels in locally advanced head?and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC?(#22931) and RTOG (# 9501). Head Neck. 2005;27:843-850.
Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, et?al. Phase II Randomized Trial of Transoral Surgery and?Low-Dose Intensity Modulated Radiation Therapy in Resectable?p16++ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN?Cancer Research Group Trial (E3311). J Clin Oncol. 2022;40:138-149.
Ma DJ, Price KA, Moore EJ, Patel SH, Hinni ML, Garcia JJ, et al.?Phase II Evaluation of Aggressive Dose De-Escalation for?Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated?Oropharynx Squamous Cell Carcinoma. J Clin Oncol. 2019;37:1909-1918.
Ma DJ, Price K, Eric MJ, Patel SH, Hinni ML, Ginos BF, et al.?Long-Term Results for MC1273, A Phase II Evaluation of?De-Escalated Adjuvant Radiation Therapy for Human Papillomavirus?Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ (HPV+?OPSCC). Int J Radiat Oncol Biol Phys. 2021;111 Suppl 3:S61.
Ma DJ, Price K, Moore EJ, Patel SH, Hinni ML, Fruth B, et al.?Non-Inferiority Margin and Nodal Analysis of De-Escalated?Adjuvant Radiation Therapy (DART) for HPV-Related Oropharyngeal?Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled?Analysis of MC1273 & MC1675. Int J Radiat Oncol Biol Phys.?2022;112:e3-4.
Ma DM, Price K, Moore EJ, Patel SH, Hinni ML, Fruth B, et al.?MC1675, a Phase III Evaluation of De-Escalated Adjuvant?Radiation Therapy (DART) vs. Standard Adjuvant Treatment for?Human Papillomavirus Associated Oropharyngeal Squamous?Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2021;111:1324.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.